"Triazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D014230
|
| MeSH Number(s) |
D03.383.129.799
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Triazoles".
Below are MeSH descriptors whose meaning is more specific than "Triazoles".
This graph shows the total number of publications written about "Triazoles" by people in this website by year, and whether "Triazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 2 | 1 | 3 |
| 2004 | 4 | 0 | 4 |
| 2005 | 2 | 1 | 3 |
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 4 | 0 | 4 |
| 2009 | 3 | 0 | 3 |
| 2010 | 2 | 4 | 6 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 3 | 4 |
| 2013 | 3 | 3 | 6 |
| 2014 | 0 | 3 | 3 |
| 2015 | 2 | 4 | 6 |
| 2016 | 3 | 1 | 4 |
| 2017 | 5 | 3 | 8 |
| 2018 | 4 | 2 | 6 |
| 2019 | 2 | 2 | 4 |
| 2020 | 2 | 1 | 3 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Triazoles" by people in Profiles.
-
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. Gastroenterology. 2021 11; 161(5):1475-1486.
-
Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant. 2020 11; 55(11):2204-2206.
-
Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy. Br J Haematol. 2020 05; 189(4):e126-e130.
-
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia. 2020 09; 34(9):2430-2440.
-
Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia. Haematologica. 2020 08; 105(8):e404-e407.
-
Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy. J Immunother Cancer. 2019 07 10; 7(1):175.
-
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. Br J Haematol. 2019 08; 186(4):549-560.
-
The impact of initiating posaconazole on tacrolimus pharmacokinetics in allogeneic stem cell transplantation. J Oncol Pharm Pract. 2020 Jan; 26(1):5-12.
-
Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma. Melanoma Res. 2018 12; 28(6):605-610.
-
XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of I?B. Mol Cancer Ther. 2018 12; 17(12):2564-2574.